Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.
about
A review of clinical practice guidelines for lung cancerAdvanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient.Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancerChallenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare SystemStereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review.A Case Series of Survival Outcomes in Patients with Advanced-stage IIIb/IV Non-small-cell Lung Cancer Treated with HangAm-Plus.Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses.Salvage stereotactic body radiotherapy for locally recurrent non-small cell lung cancer after sublobar resection and i(125) vicryl mesh brachytherapy.Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center.Second-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: evaluation of performance status and health-related quality of life.Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancerStereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation.Phase I study of docetaxel plus S-1 combination chemotherapy for recurrent non-small cell lung cancer.Should salvage surgery be considered for local recurrence after definitive chemoradiation in locally advanced non-small cell lung cancer?Non-small-cell lung cancer: treatment of late stage disease: chemotherapeutics and new frontiers.Current Topics on Salvage Thoracic Surgery in Patients with Primary Lung Cancer.The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statementPhase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment.Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer.Special topics in immunotherapy and radiation therapy: reirradiation and palliationLung reirradiation with stereotactic body radiotherapy (SBRT).Salvage thoracic surgery in patients with lung cancer: potential indications and benefits.Feasibility of carbon-ion radiotherapy for re-irradiation of locoregionally recurrent, metastatic, or secondary lung tumors.Particle therapy in non-small cell lung cancer.[Correlation between pre-treatment anemia and prognosis in non-small cell lung cancer patients].Reirradiation for locoregionally recurrent non-small cell lung cancer
P2860
Q26999236-EA7A551A-FF7B-4E49-9EBA-F6C573200231Q33632656-8C69197E-A8F3-49E5-87B4-A85FF6E98169Q33824712-2AEFB826-8250-445F-861C-862D28D5F0FDQ34608597-9F9E9D70-63A9-4EE2-9C2B-F57815175B39Q34667302-12E6AE6E-834C-4D19-ADE3-1551AE30355CQ35093484-B1DACAF8-CD90-4C44-B969-672A2C2CC8DFQ35143867-78C173B4-63EE-483C-8A1E-9DB538AFCD27Q35591365-E594041A-5005-48F1-AB7C-4780EAE09BA3Q35695893-900E8DC5-3F80-4662-9CF8-845A40783D67Q35802325-31F33A58-398E-4491-AE2E-0F3AB8FC76F0Q36021095-8694D3D6-29C6-4857-B67B-ABBC945B1893Q36105945-1AB86065-A395-487C-9A7A-133F389084A7Q36142343-8D160C3E-067F-4492-94CC-BCC73D04A49DQ36476122-1E0D8754-4F81-479F-AECB-0A56AB5F1E19Q37008086-A8A34CB5-ED17-4C94-8004-3965C5CBE03EQ37073674-C648D234-9DE1-4A4C-8903-79D469B61ECEQ37102068-8C497C58-7F8A-4255-892C-C4D4ACD19CF4Q37539257-862542C8-9054-4758-A5FC-BBBF9E2F04A5Q37735284-F4F54B50-2A16-4092-81B4-6AAAD378F3EDQ38026294-E6D65FF7-0C92-4C26-8D63-F66461BBA8FDQ38771929-5D38FBCA-A976-45B5-AB2A-A3D01F118CB8Q47121935-21CEB312-1D46-454D-87D5-926B0B2EC5D7Q48192357-6ED2A707-A8E6-4F66-9862-7A512213791FQ55020011-151CE733-6AC4-4DB9-A79B-E301A6AE021EQ55073985-7784E35A-4233-4921-8E53-79FFE226FE0AQ55432746-A252DB3A-E213-40DB-BB86-89400EDD21E2Q58804832-5D17C156-CE11-4538-99DE-FBEBC8CBFC8E
P2860
Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Second-line or subsequent syst ...... review and practice guideline.
@ast
Second-line or subsequent syst ...... review and practice guideline.
@en
type
label
Second-line or subsequent syst ...... review and practice guideline.
@ast
Second-line or subsequent syst ...... review and practice guideline.
@en
prefLabel
Second-line or subsequent syst ...... review and practice guideline.
@ast
Second-line or subsequent syst ...... review and practice guideline.
@en
P2093
P1476
Second-line or subsequent syst ...... review and practice guideline
@en
P2093
J A Mackay
Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care
P304
P356
10.1016/S1556-0864(15)31641-5
P577
2006-11-01T00:00:00Z